NR4A1 and cancer: We analyzed the hormone receptor status separately and found that in patients with hormone receptor–positive cancer, ILC resulted in worse survival than IDC after 10 years of diagnosis, with HRs of 1.55 (95% CI, 1.37-1.75; P < .001) in the SEER database, 2.27 (95% CI, 1.01-5.10; P = .05) in the KBCR database, and 2.12 (95% CI, 0.98-4.60; P = .06) in the AMCR database.